Drug Profile


Alternative Names: BAL 4815; RO 00 94815

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Astellas Pharma; Basilea Pharmaceutica
  • Class Antifungals; Nitriles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Mycoses

Most Recent Events

  • 26 Oct 2016 Pharmacokinetics data from a preclinical study presented at the IDWeek 2016
  • 14 Sep 2016 Isavuconazole licensed to Asahi Kasei Pharma in Japan
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Mycoses(In volunteers) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top